Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.
* denotes publications from the CTD2 initiative that are results of intra-Network collaborations
The authors propose a framework for the systematic discovery of genetic alterations that are causal determinants of disease.
The authors' findings uncover an unexpected neomorphic role for PIK3R1R348∗ and neighboring truncation mutations in cellular signaling, providing a rationale for therapeutic targeting of these mutant tumors.
Researchers identify potent siRNAs against RAS to explore potential combination RNAi therapies for KRAS-mutant cancer.
When combined with genomic characterization of these cell lines, the dataset presented here facilitates the linkage of genetic dependencies with specific cellular contexts.
Using an inducible and reversible transgenic RNAi mouse model, researchers show that strong suppression of the BET protein Brd4 in adult animals has dramatic effects in multiple tissues.
Genomic profiling and analysis of patients with precursor B-cell ALL and those with Ph-like ALL showed that the genomic alterations that characterized Ph-like ALL might be amenable to inhibition with tyrosine kinase inhibitors.
Researchers find that inhibition of Aurora kinase A leads to degradation of MYCN protein in MYCN-driven cancers
In this study, researchers address the problem of drug susceptibility prediction against a panel of drugs in a multitask learning framework by formulating a novel Bayesian algorithm that combines kernel-based non-linear dimensionality reduction and binary classification (or regression).
Researchers document the metastatic differentiation and genetic heterogeneity of diffuse gastric cancer and reveal the potential metastatic role of TGFBR2 loss-of-function.